Table 3.
Multivariable associations of gSOS tertiles with fracture risk in breast cancer patients on aromatase inhibitors (AI).
| gSOS PGS | Model 1a | Model 2b | Model 3c | |||
|---|---|---|---|---|---|---|
| HR (95% CI) | P trend | HR (95% CI) | P trend | HR (95% CI) | P trend | |
| gSOS continuous | 0.54 (0.42–0.69) | 1.76E-06 | 0.57 (0.44-0.75) | 3.35E-05 | 0.74 (0.53, 1.05) | 0.09 |
| Tertile 1 | 1.00 | 1.78E-05 | 1.00 | 1.64E-05 | 1.00 | 3.33E-02 |
| Tertile 2 | 0.61 (0.47–0.81) | – | 0.61 (0.46–0.80) | – | 0.71 (0.49–1.02) | – |
| Tertile 3 | 0.53 (0.40–0.71) | – | 0.53 (0.40–0.70) | – | 0.62 (0.42–0.91) | – |
aModel 1: adjusted for age at diagnosis
bModel 2: adjusted for age at diagnosis, prior history of osteoporosis, prior history of major fracture, race and ethnicity, cancer treatment, and AI treatment as a time-varying variable
cModel 3: adjusted for the same covariates as in Model 2 plus BMD at the hip.